Mitogen-Activated Protein Kinase Kinases
"Mitogen-Activated Protein Kinase Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine-threonine protein kinase family whose members are components in protein kinase cascades activated by diverse stimuli. These MAPK kinases phosphorylate MITOGEN-ACTIVATED PROTEIN KINASES and are themselves phosphorylated by MAP KINASE KINASE KINASES. JNK kinases (also known as SAPK kinases) are a subfamily.
| Descriptor ID |
D020929
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.565 D08.811.913.696.620.682.725.200 D12.644.360.440 D12.776.476.440
|
| Concept/Terms |
Mitogen-Activated Protein Kinase Kinases- Mitogen-Activated Protein Kinase Kinases
- Mitogen Activated Protein Kinase Kinases
- MAPKK
- MAPKKs
- MAP Kinase Kinases
- Kinase Kinases, MAP
- Kinases, MAP Kinase
- MAPK Kinases
- Kinases, MAPK
- Map Kinase Kinase
- Kinase Kinase, Map
- Kinase, Map Kinase
MAPK-ERK Kinases- MAPK-ERK Kinases
- Kinases, MAPK-ERK
- MAPK ERK Kinases
- MEKs
- MAP-ERK Kinase
- Kinase, MAP-ERK
- MAP ERK Kinase
|
Below are MeSH descriptors whose meaning is more general than "Mitogen-Activated Protein Kinase Kinases".
Below are MeSH descriptors whose meaning is more specific than "Mitogen-Activated Protein Kinase Kinases".
This graph shows the total number of publications written about "Mitogen-Activated Protein Kinase Kinases" by people in this website by year, and whether "Mitogen-Activated Protein Kinase Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 2 | 3 | 5 |
| 1996 | 1 | 2 | 3 |
| 1997 | 1 | 3 | 4 |
| 1998 | 4 | 1 | 5 |
| 1999 | 9 | 2 | 11 |
| 2000 | 3 | 5 | 8 |
| 2001 | 3 | 8 | 11 |
| 2002 | 5 | 6 | 11 |
| 2003 | 6 | 9 | 15 |
| 2004 | 1 | 5 | 6 |
| 2005 | 5 | 6 | 11 |
| 2006 | 4 | 1 | 5 |
| 2007 | 2 | 5 | 7 |
| 2008 | 0 | 3 | 3 |
| 2009 | 4 | 3 | 7 |
| 2010 | 2 | 7 | 9 |
| 2011 | 3 | 2 | 5 |
| 2012 | 6 | 3 | 9 |
| 2013 | 2 | 3 | 5 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 3 | 5 |
| 2016 | 1 | 2 | 3 |
| 2017 | 3 | 3 | 6 |
| 2018 | 1 | 2 | 3 |
| 2019 | 2 | 1 | 3 |
| 2020 | 4 | 3 | 7 |
| 2021 | 3 | 5 | 8 |
| 2022 | 2 | 10 | 12 |
| 2023 | 1 | 8 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mitogen-Activated Protein Kinase Kinases" by people in Profiles.
-
Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors. Cancer Res Commun. 2023 12 28; 3(12):2623-2639.
-
Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis. Blood Adv. 2023 08 08; 7(15):3984-3992.
-
Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice. Melanoma Res. 2023 10 01; 33(5):406-416.
-
Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer. Mol Cancer Ther. 2023 08 01; 22(8):962-975.
-
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.
-
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol. 2023 08; 92(2):107-118.
-
Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. Cancer Immunol Res. 2023 05 03; 11(5):558-569.
-
Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo. PLoS One. 2023; 18(3):e0281063.
-
Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. ESMO Open. 2023 04; 8(2):100788.
-
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023 01 10; 41(2):186-197.